GSK PLC (GLAXF)
22.03
+0.89
(+4.22%)
USD |
OTCM |
May 07, 10:51
GSK Price to Book Value: 5.142 for May 7, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 06, 2024 | 4.934 |
| May 03, 2024 | 4.934 |
| May 02, 2024 | 4.901 |
| May 01, 2024 | 4.901 |
| April 30, 2024 | 4.854 |
| April 29, 2024 | 4.971 |
| April 26, 2024 | 4.633 |
| April 25, 2024 | 4.633 |
| April 24, 2024 | 4.633 |
| April 23, 2024 | 4.560 |
| April 22, 2024 | 4.739 |
| April 19, 2024 | 4.714 |
| April 18, 2024 | 4.714 |
| April 17, 2024 | 4.714 |
| April 16, 2024 | 4.714 |
| April 15, 2024 | 4.714 |
| April 12, 2024 | 4.684 |
| April 11, 2024 | 4.786 |
| April 10, 2024 | 4.864 |
| April 09, 2024 | 4.864 |
| April 08, 2024 | 4.843 |
| April 05, 2024 | 4.843 |
| April 04, 2024 | 4.878 |
| April 03, 2024 | 4.920 |
| April 02, 2024 | 4.879 |
| Date | Value |
|---|---|
| April 01, 2024 | 4.691 |
| March 31, 2024 | |
| March 28, 2024 | 5.145 |
| March 27, 2024 | 5.095 |
| March 26, 2024 | 5.095 |
| March 25, 2024 | 5.287 |
| March 22, 2024 | 4.960 |
| March 21, 2024 | 5.012 |
| March 20, 2024 | 4.964 |
| March 19, 2024 | 4.970 |
| March 18, 2024 | 5.000 |
| March 15, 2024 | 5.182 |
| March 14, 2024 | 5.120 |
| March 13, 2024 | 5.162 |
| March 12, 2024 | 5.024 |
| March 11, 2024 | 5.024 |
| March 08, 2024 | 5.124 |
| March 07, 2024 | 5.181 |
| March 06, 2024 | 5.050 |
| March 05, 2024 | 5.050 |
| March 04, 2024 | 5.050 |
| March 01, 2024 | 5.012 |
| February 29, 2024 | 5.010 |
| February 28, 2024 | 5.030 |
| February 27, 2024 | 5.030 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
2.808
Minimum
Sep 22 2022
23.20
Maximum
Jul 30 2019
6.584
Average
5.129
Median
Feb 22 2024
Price to Book Value Benchmarks
| Adaptimmune Therapeutics PLC | 6.871 |
| Biodexa Pharmaceuticals Plc | 0.7359 |
| Verona Pharma PLC | 4.785 |
| NuCana PLC | 0.4393 |
| Autolus Therapeutics PLC | 9.626 |
Price to Book Value Related Metrics
| PE Ratio | 17.27 |
| PS Ratio | 2.489 |
| Price to Free Cash Flow | 14.61 |
| Price | 22.03 |
| Earnings Yield | 5.79% |
| Market Cap | 89.85B |
| Operating PE Ratio | 11.32 |
| Normalized PE Ratio | 15.64 |